The anti-inflammatory effects of prostaglandins

Journal of Investigative Medicine

Volumn 57, Issue 6, 2009, Pages 703-708

  Scher, Jose U ^a,b   Pillinger, Michael H ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Cardiovascular disease; Cyclooxygenase; Inflammation; NSAID; Prostaglandin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ABC TRANSPORTER A1; CIGLITAZONE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN J2; TUMOR NECROSIS FACTOR ALPHA; UO 126;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CELL ADHESION; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG EFFECT; ENZYME INHIBITION; FOAM CELL; HEART PROTECTION; HUMAN; INFLAMMATION; LIPID STORAGE; MACROPHAGE; NEUTROPHIL; NONHUMAN; PAIN; PHAGOCYTOSIS; PROTEIN EXPRESSION; REPERFUSION INJURY; SMOOTH MUSCLE CONTRACTION; VASCULAR DISEASE; VASODILATATION;

ANIMALIA;

CORONARY ARTERY DISEASE; HUMANS; INFLAMMATION; PROSTAGLANDINS;

EID: 70349263442     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31819aaa76     Document Type: Conference Paper

References (63)

1. 2 enzymes. Prostaglandins Other Lipid Mediat. 2002;68-69:3-58.
2. 2. J Biol Chem. 2001;276:34918-34927.
3. 2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem. 2003;278:37937-37947.
4. 2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem. 2000;275:32783-32792.
5. 2 production in the rat adjuvant-induced arthritis model. J Immunol. 2003;170:4738-4744.
6. 2 biosynthesis. J Biol Chem. 2000;275:32775Y32782.
7. Shen RF, Tai HH. Thromboxanes: synthase and receptors. J Biomed Sci. 1998;5:153-172.
8. Kanaoka Y, Fujimori K, Kikuno R, et al. Structure and chromosomal localization of human and mouse genes for hematopoietic prostaglandin D synthase. Conservation of the ancestral genomic structure of sigma-class glutathione S-transferase. Eur J Biochem. 2000;267: 3315-3322.
9. Urade Y, Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta. 2000;1482:259-271.
10. Helliwell RJ, Adams LF, Mitchell MD. Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids. 2004;70:101-113.
11. Ruan KH, Dogne JM. Implications of the molecular basis of prostacyclin biosynthesis and signaling in pharmaceutical designs. Curr Pharm Des. 2006;12:925-941.
12. Hayaishi O. Molecular genetic studies on sleep-wake regulation, with special emphasis on the prostaglandin D2 system. J Appl Physiol. 2002;92:863-868.
13. 2 in sleep-wake regulation: recent progress and perspectives. Neuroscientist. 2002;8:12-15.
14. 2 is selectively elevated in cerebrospinal fluid of advanced sleeping sickness patients. Trans R Soc Trop Med Hyg. 1990;84:795-799.
15. 2 for induction of human articular chondrocyte apoptosis in arthritis. J Biol Chem. 2004;279:37939-37950.
16. Attur M, Dave M, Leung M, et al. Differential expression of brain PGD2 synthase in OA cartilage: role and mechanism of action of PGD2 in eicosanoid metabolism. Arthritis Rheum. 2003;48:430.
17. Wright DH, Metters KM, Abramovitz M, et al. Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998;123:1317-1324.
18. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001;193: 255-261.
19. Fitzpatrick FA, Wynalda MA. Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro. J Biol Chem. 1983;258:11713-11718.
20. 2 metabolite generated during inflammatory processes. J Biol Chem. 2002;277:10459-10466.
21. 2: the anti-inflammatory prostaglandin? Clin Immunol. 2005;114:100-109.
22. Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature. 2000;403:103-108.
23. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci U S A. 2000;97:4844-4849.
24. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
25. Jiang C, Ting AT, Seed B. PPAR-F agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
26. 2. J Biol Chem. 1999;274:17042-17048.
27. Ide T, Egan K, Bell-Parikh LC, et al. Activation of nuclear receptors by prostaglandins. Thrombosis research. 2003;110:311-315.
28. 2 and the ligation of PPARγ. J Clin Invest. 2003;112:945-955.
29. 2 inactivated murine macrophages. Mol Cell Biol. 2000;20:1692-1698.
30. Wilmer WA, Dixon C, Lu L, et al. A cyclopentenone prostaglandin activates mesangial MAP kinase independently of PPAR-F. Biochem Biophys Res Commun. 2001;281:57-62.
31. Valledor AF, Ricote M. Nuclear receptor signaling in macrophages. Biochem Pharmacol. 2004;67:201-212.
32. Azuma Y, Shinohara M, Wang PL, et al. 15-Deoxy-delta(12,14)-prostaglandin J2 inhibits IL-10 and IL-12production by macrophages. Biochem Biophys Res Commun. 2001;283:344-346.
33. Akahoshi T, Namai R, Murakami Y, et al. Rapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals. Arthritis Rheum. 2003;48:231-39.
34. Marx N, Mach F, Sauty A, et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-F-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000;164:6503-6508.
35. Chen NG, Han X. Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium. Biochem Biophys Res Commun. 2001;282:717-722.
36. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest. 2000;106:189-197.
37. Murakami Y, Akahoshi T, Hayashi I, et al. Inhibition of monosodium urate monohydrate crystal-induced acute inflammation by retrovirally transfected prostaglandin D synthase. Arthritis Rheum. 2003;48:2931-2941.
38. 2. Proc Natl Acad Sci U S A. 2007;104:20979-20984.
39. Gilroy DW, Colville-Nash PR,Willis D, et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med. 1999;5:698-701.
40. 2α by selective cyclooxygenase 2 inhibitors accounts for reduced rat leukocyte migration. Inflammation. 2005;29:163-169.
41. 2α produced by inducible cyclooxygenase may contribute to the resolution of inflammation. Inflammopharmacology. 2005;12:473-476; discussion 477-480.
42. 1 treatment of NZB/NZW F1 hybrid mice. II. Prevention of glomerulonephritis. Arthritis Rheum. 1977;20:1449-1456.
43. 1 on adjuvant arthritis. Nature. 1971;234:304-305.
44. Zurier RB, Sayadoff DM, Torrey AB, et al. Prostaglandin E treatment of NZB/NZW mice. Arthritis Rheum. 1977;20:723-728.
45. 1. Prostaglandins. 1994;48:187-195.
46. 2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol. 2004;173:559-565.
47. 1 inhibits chemoattractant-induced mitogen-activated protein kinase activity in human neutrophils. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:311-316.
48. Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol. 2005;115:118-128.
49. Pillinger MH, Dinsell V, Apsel B, et al. Regulation of metalloproteinases and NF-κB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: contrasting effects of nabumetone and 6MNA. Br J Pharmacol. 2004;142:973-982.
50. Pillinger MH, Rosenthal PB, Tolani SN, et al. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J Immunol. 2003;171:6080-6089.
51. Wang T, Zhang X, Li JJ. The role of NF-κB in the regulation of cell stress responses. Int Immunopharmacol. 2002;2:1509-1520.
52. 2 dissociates nuclear trafficking of individual NF-κB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. J Immunol. 2005;175:6924-6930.
53. Pillinger MH, Marjanovic N, Kim SY, et al. Matrix metalloproteinase secretion by gastric epithelial cells is regulated by E prostaglandins and MAPKs. J Biol Chem. 2005;280:9973-9979.
54. Tchetina EV, Di Battista JA, Zukor DJ, et al. Prostaglandin PGE2 at very low concentrations suppresses collagen cleavage in cultured human osteoarthritic articular cartilage: this involves a decrease in expression of proinflammatory genes, collagenases and COL10A1, a gene linked to chondrocyte hypertrophy. Arthritis Res Ther. 2007;9:R75.
55. 2 and ciglitazone, in reperfusion injury: role of nuclear factor-κB, heat shock factor 1, and Akt. Shock. 2007;28:554-563.
56. Chan ES, Zhang H, Fernandez P, et al. Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis Res Ther. 2007;9:R4.
57. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4-15.
58. Cipollone F, Fazia M, Iezzi A, et al. Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler Thromb Vasc Biol. 2004;24: 1259-1265.
59. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science. 1994;265:956-959.
60. Pillinger MH, Capodici C, Rosenthal P, et al. Modes of action of aspirin-like drugs: salicylates inhibit Erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci U S A. 1998;95:14540-14545.
61. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232-235.
62. Chiang N, Arita M, Serhan CN. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids. 2005;73:163-177.
63. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids. 2005;73:141-162.